Open AccessExploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy
Author(s) -
Z. Walker,
Beau M. Idler,
Lorraine N. Davis,
Brett M. Stevens,
Michael J. VanWyngarden,
Denis Ohlstrom,
Shelby C. Bearrows,
Andrew Hammes,
Clayton A. Smith,
Craig T. Jordan,
Tomer M. Mark,
Peter A. Forsberg,
Daniel W. Sherbenou
Publication year - 2021
Publication title -
clinical cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.427
H-Index - 324
eISSN - 1557-3265
pISSN - 1078-0432
DOI - 10.1158/1078-0432.ccr-20-2246
Subject(s) - multiple myeloma , daratumumab , medicine , cancer research , bortezomib , oncology
The prognosis of patients with multiple myeloma who are resistant to proteasome inhibitors, immunomodulatory drugs (IMiD), and daratumumab is extremely poor. Even B-cell maturation antigen-specific chimeric antigen receptor T-cell therapies provide only a temporary benefit before patients succumb to their disease. In this article, we interrogate the unique sensitivity of multiple myeloma cells to the alternative strategy of blocking protein translation with omacetaxine.